NASDAQ:GILD
Gilead Sciences, Inc.
Gilead Sciences, Inc.'s revenue grew 2.4% in fiscal 2025 to $29.4B while operating margin rose to 34.0%. Free cash flow was $9.5B, 32.1% of revenue.Summary generated from Gilead Sciences, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$29.4B
Revenue growth+2.4%
Revenue, 5-yr CAGR+3.6%
Gross margin78.8%
Operating margin34.0%
Net margin28.9%
ROIC22.9%
Return on equity40.5%
Debt / equity1.10
Free cash flow$9.5B
FCF margin32.1%
Share count change+0.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 27.3 | 27.3 | 27.1 | 28.8 | 29.4 |
| Operating income | 9.9 | 7.3 | 7.6 | 1.7 | 10.0 |
| Net income | 6.2 | 4.6 | 5.7 | 0.5 | 8.5 |
| Free cash flow | 10.8 | 8.3 | 7.4 | 10.3 | 9.5 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Sep 23, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KEntry into a material agreement
May 20, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - 8-KResults of a shareholder vote
May 4, 2026